Get the Stockscreener App
31.84
1.60%
0.50
After Hours:
31.84
Soleno Therapeutics Inc stock is traded at $31.84, with a volume of 1.26M.
It is up +1.60% in the last 24 hours and down -22.36% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR.
See More
Previous Close:
$31.34
Open:
$32.15
24h Volume:
1.26M
Relative Volume:
0.83
Market Cap:
$1.64B
Revenue:
$190.41M
Net Income/Loss:
$20.48M
P/E Ratio:
142.91
EPS:
0.2228
Net Cash Flow:
$46.66M
1W Performance:
-2.93%
1M Performance:
-22.36%
6M Performance:
-49.23%
1Y Performance:
-36.38%
1-Day Range:
$31.55
$33.45
1-Week Range:
$30.11
$34.20
52-Week Range:
$30.11
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
31.84 | 1.62B | 190.41M | 20.48M | 46.66M | 0.2228 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Oct-07-25 | Initiated | Goldman | Buy |
| Aug-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-23-25 | Initiated | TD Cowen | Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
ROSEN, HIGHLY REGARDED INVESTOR RIGHTS COUNSEL, Encourages Soleno Therapeutics, Inc. Investors ... - Bluefield Daily Telegraph
Soleno Therapeutics, Inc. (SLNO) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - The Globe and Mail
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) ... - Bluefield Daily Telegraph
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud - GuruFocus
Investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO) Seeking RecoveryContact Kaplan Fox Before Deadline on May 5, 2026 - NewMediaWire
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application - GlobeNewswire
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Commercial Viability Risks: Levi & Korsinsky - Business Wire
Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman - PR Newswire
DEADLINE ALERT for BSX, EOSE, SLNO, and NKTR: The Law - GlobeNewswire
Soleno Therapeutics (NASDAQ:SLNO) Moves With Broader Nasdaq Index Decline - Kalkine Media
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm - PR Newswire
JPMorgan Chase & Co. Raises Stock Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Sets New 1-Year LowWhat's Next? - MarketBeat
Robbins LLP Urges SLNO Stockholders Who Lost Money Investing in Soleno Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action - PR Newswire
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit - ChartMill
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities - GlobeNewswire
SLNO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Deadline Alert: Soleno Therapeutics, Inc. (SLNO) - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Soleno - GlobeNewswire
Soleno Therapeutics Faces Investor Lawsuit Over Alleged Safety Concealment in VYKAT XR Drug Launch - TipRanks
Soleno Therapeutics (SLNO) Faces Securities Class Action - GlobeNewswire
Notice to Long-Term Shareholders of ASP Isotopes Inc. - GlobeNewswire
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
A Look At Soleno Therapeutics (SLNO) Valuation After Oppenheimer’s Vykat XR Launch Outlook - Sahm
SLNO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - Sahm
SLNO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Soleno - GlobeNewswire
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure ... - Caledonian Record
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO - GlobeNewswire Inc.
INVESTOR DEADLINE: Soleno Therapeutics Inc. (SLNO) - GlobeNewswire
Soleno Therapeutics (NASDAQ:SLNO) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
User - The Chronicle-Journal
Price-Driven Insight from (SLNO) for Rule-Based Strategy - Stock Traders Daily
Should Soleno’s Governance Shift, Vykat XR Launch Concerns and Lawsuit Require Action From Soleno Therapeutics (SLNO) Investors? - simplywall.st
Soleno Therapeutics Investors File Securities Fraud Lawsuit - National Today
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc.SLNO - PR Newswire
SLNO SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on - GlobeNewswire
Soleno Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | 1SLNO | US8342033094 - marketscreener.com
NASDAQ: SLNO: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Soleno Therapeutics, Inc. - ChartMill
SLNO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - TMX Newsfile
A Look At Soleno Therapeutics (SLNO) Valuation As Oppenheimer Updates Vykat XR Launch And 2026 Sales Outlook - Yahoo Finance
Soleno Therapeutics Sued for Securities Law Violations - National Today
Soleno Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsSLNO - Lelezard
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSLNO - PR Newswire
Soleno Lawsuit Puts DCCR Safety Disclosures And Growth Story Under Scrutiny - simplywall.st
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure ... - Caledonian Record
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Soleno - GlobeNewswire
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):